<?xml version='1.0' encoding='utf-8'?>
<document id="32235864"><sentence text="Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer."><entity charOffset="0-10" id="DDI-PubMed.32235864.s1.e0" text="Alflutinib" /></sentence><sentence text="Alflutinib (AST2818) is a third-generation epidermal growth factor receptor (EGFR) inhibitor that inhibits both EGFR-sensitive mutations and T790M mutations"><entity charOffset="0-10" id="DDI-PubMed.32235864.s2.e0" text="Alflutinib" /></sentence><sentence text=" Previous study has shown that after multiple dosages, alflutinib exhibits nonlinear pharmacokinetics and displays a time- and dose-dependent increase in the apparent clearance, probably due to its self-induction of cytochrome P450 (CYP) enzyme"><entity charOffset="55-65" id="DDI-PubMed.32235864.s3.e0" text="alflutinib" /></sentence><sentence text=" In this study, we investigated the CYP isozymes involved in the metabolism of alflutinib and evaluated the enzyme inhibition and induction potential of alflutinib and its metabolites"><entity charOffset="79-89" id="DDI-PubMed.32235864.s4.e0" text="alflutinib" /><entity charOffset="153-163" id="DDI-PubMed.32235864.s4.e1" text="alflutinib" /><pair ddi="false" e1="DDI-PubMed.32235864.s4.e0" e2="DDI-PubMed.32235864.s4.e0" /><pair ddi="false" e1="DDI-PubMed.32235864.s4.e0" e2="DDI-PubMed.32235864.s4.e1" /></sentence><sentence text=" The data showed that alflutinib in human liver microsomes (HLMs) was metabolized mainly by CYP3A4, which could catalyze the formation of AST5902"><entity charOffset="22-32" id="DDI-PubMed.32235864.s5.e0" text="alflutinib" /></sentence><sentence text=" Alflutinib did not inhibit CYP isozymes in HLMs but could induce CYP3A4 in human hepatocytes" /><sentence text=" Rifampin is a known strong CYP3A4 inducer and is recommended by the FDA as a positive control in the CYP3A4 induction assay"><entity charOffset="1-9" id="DDI-PubMed.32235864.s7.e0" text="Rifampin" /></sentence><sentence text=" We found that the induction potential of alflutinib was comparable to that of rifampin"><entity charOffset="42-52" id="DDI-PubMed.32235864.s8.e0" text="alflutinib" /><entity charOffset="79-87" id="DDI-PubMed.32235864.s8.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.32235864.s8.e0" e2="DDI-PubMed.32235864.s8.e0" /><pair ddi="false" e1="DDI-PubMed.32235864.s8.e0" e2="DDI-PubMed.32235864.s8.e1" /></sentence><sentence text=" The Emax of CYP3A4 induction by alflutinib in three lots of human hepatocytes were 9" /><sentence text="24-, 11" /><sentence text="2-, and 10" /><sentence text="4-fold, while the fold-induction of rifampin (10 μM) were 7"><entity charOffset="36-44" id="DDI-PubMed.32235864.s12.e0" text="rifampin" /></sentence><sentence text="22-, 19" /><sentence text="4- and 9" /><sentence text="46-fold, respectively" /><sentence text=" The EC50 of alflutinib-induced CYP3A4 mRNA expression was 0"><entity charOffset="13-23" id="DDI-PubMed.32235864.s16.e0" text="alflutinib" /></sentence><sentence text="25 μM, which was similar to that of rifampin"><entity charOffset="36-44" id="DDI-PubMed.32235864.s17.e0" text="rifampin" /></sentence><sentence text=" In addition, AST5902 exhibited much weak CYP3A4 induction potential compared to alflutinib"><entity charOffset="81-91" id="DDI-PubMed.32235864.s18.e0" text="alflutinib" /></sentence><sentence text=" Given the plasma exposure of alflutinib and AST5902, both are likely to affect the pharmacokinetics of CYP3A4 substrates"><entity charOffset="30-40" id="DDI-PubMed.32235864.s19.e0" text="alflutinib" /><entity charOffset="45-52" id="DDI-PubMed.32235864.s19.e1" text="AST5902" /><pair ddi="false" e1="DDI-PubMed.32235864.s19.e0" e2="DDI-PubMed.32235864.s19.e0" /><pair ddi="false" e1="DDI-PubMed.32235864.s19.e0" e2="DDI-PubMed.32235864.s19.e1" /></sentence><sentence text=" Considering that alflutinib is a CYP3A4 substrate and a potent CYP3A4 inducer, drug-drug interactions are expected during alflutinib treatment"><entity charOffset="18-28" id="DDI-PubMed.32235864.s20.e0" text="alflutinib" /><entity charOffset="123-133" id="DDI-PubMed.32235864.s20.e1" text="alflutinib" /><pair ddi="false" e1="DDI-PubMed.32235864.s20.e0" e2="DDI-PubMed.32235864.s20.e0" /><pair ddi="false" e1="DDI-PubMed.32235864.s20.e0" e2="DDI-PubMed.32235864.s20.e1" /></sentence><sentence text="" /></document>